NasdaqGM:GPCRPharmaceuticals
Structure Therapeutics (GPCR) Is Down 7.2% After Strong Phase 2 Oral GLP‑1 Obesity Data – Has The Bull Case Changed?
Structure Therapeutics previously reported encouraging Phase 2 ACCESS II trial results for its oral GLP-1 receptor agonist aleniglipron, showing up to 16.3% weight reduction in adults with obesity and outlining plans to meet the FDA in Q2 2026 ahead of Phase 3 trials in the second half of 2026.
The data position aleniglipron as one of the most effective oral GLP-1 candidates so far, highlighting a potentially meaningful differentiation versus other pill-based obesity treatments.
Next, we...